The first results of the CARMEN-LC05-study
Dr Charlotte De Bondt from the University Hospital Antwerp comments on the first results of the CARMEN-LC05-study. At ELCC 2023, data on the efficacy and safety of tusamitamab ravtansine in combination with pembrolizumab with or without chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC were communicated.
With the support of:
